Proceedings from a CME symposium held at the 2012 ASCO Annual Meeting. Featuring perspectives from Drs Dirk Arnold, Howard S Hochster, Eric Van Cutsem, Alan P Venook and John R Zalcberg. (Video Program)
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Dirk Arnold, MD
Director, Hubertus Wald Tumor Center
University Cancer Center Hamburg
University Hospital Eppendorf
Hamburg, Germany
Advisory Committee and Speakers Bureau: Amgen Inc, Merck Serono, Roche Laboratories Inc, Sanofi; Consulting Agreement: Bayer HealthCare Pharmaceuticals; Paid Research: Roche Laboratories Inc.
Howard S Hochster, MD
Associate Director (Clinical Research)
Yale Cancer Center
Professor of Medicine
Yale School of Medicine
New Haven, Connecticut
Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Myriad Genetics Inc, Sanofi; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, Sanofi; Speakers Bureau: Genomic Health Inc.
Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospital Gasthuisberg/Leuven
Leuven, Belgium
Research Grants: Amgen Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.
Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
Advisory Committee: Myriad Genetics Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline.
John R Zalcberg, MBBS, PhD
Chief Medical Officer and Executive Director
Cancer Medicine
Peter MacCallum Cancer Centre
Melbourne, Australia
Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Research Support: Abbott Laboratories, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genzyme Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Speakers Bureau: Merck Serono, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by an educational grant from Regeneron Pharmaceuticals and Sanofi.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: September 2012
Expiration date: September 2013
Introduction: Dr Love | |
Module 1 – Dr Hochster: Patients with Potentially Resectable Liver Mets |
|
Module 2 – Dr Zalcberg: Front-Line Treatment of mCRC |
|
Module 3 – Prof Van Cutsem: Second-Line Treatment of mCRC |
|
Module 4 – Dr Arnold: Long-Term Management of mCRC |
|
Module 5 – Dr Venook: Synchronous Primary CRC and Metastases |
Watch video
(WiFi is recommended for best performance):